Teknova Opens New GMP Manufacturing Facility for Life Sciences Reagents

News
Article

The launch of Alpha Teknova’s new manufacturing facility in Hollister, Calif., increases its capacity for custom reagents for life sciences applications.

Alpha Teknova (Teknova), a US-based producer of critical reagents for novel therapies, vaccines, and molecular diagnostics, has opened its newest good manufacturing practice (GMP)-certified production facility in Hollister, Calif., which increases its capacity for custom, high-quality reagents for use in life sciences. The facility is expected to enable faster bioprocessing and gene therapy development, bringing products to the clinic faster, according to an Aug. 9, 2023 company press release.

The new facility, which was previously operational for research-grade production, now adds more than 10,000 ft2 of GMP-certified ISO cleanrooms. Teknova gets a three-fold increase in overall manufacturing capacity with expanded formulation, dispensing, cleanroom, and warehouse space. The facility also includes increased automation to support single-use needs and offers animal-free and endotoxin-controlled environments.

“Our team has worked tirelessly over the past two years to build our new GMP-certified production facility here in Hollister, and its opening represents a momentous milestone in our company’s evolution,” said Stephen Gunstream, Teknova’s president and CEO, in the press release. “We kept hearing from our customers that they wanted a partner who could support them with custom reagent manufacturing as they scale from research, through process development, and into clinical trials, particularly in batch volumes of less than 2000 liters. We built this facility to do just that [and] we look forward to leveraging our facility's modular manufacturing capabilities to continue supporting our customers throughout various stages of their lifecycle.”

Source: Alpha Teknova

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Related Content